<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04645953</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC 010-201</org_study_id>
    <nct_id>NCT04645953</nct_id>
  </id_info>
  <brief_title>Staccato GranisetronÂ® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy&#xD;
      and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes&#xD;
      of stereotypical vomiting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of&#xD;
      Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting&#xD;
      Syndrome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2021</start_date>
  <completion_date type="Anticipated">January 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of vomiting/retching events in the 2 hours following treatment.</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events as a measure of safety</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cyclic Vomiting Syndrome</condition>
  <arm_group>
    <arm_group_label>1mg AZ010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3mg AZ010</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>3mg AZ-010</intervention_name>
    <description>Subject will receive a single inhaled dose (3mg)</description>
    <arm_group_label>3mg AZ010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>1mg AZ010</intervention_name>
    <description>Subject will receive a single inhaled dose (1mg)</description>
    <arm_group_label>1mg AZ010</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Staccato Placebo</intervention_name>
    <description>Subject will receive a single inhaled dose (Staccato Placebo)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males and females between 18 and 60 years of age, inclusive at the time of&#xD;
             signing the informed consent document.&#xD;
&#xD;
          -  Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria.&#xD;
&#xD;
          -  Otherwise healthy, as determined by the responsible physician, based on a medical&#xD;
             evaluation including history, physical examination, vital signs, electrocardiograms&#xD;
             (ECGs) and laboratory tests assessed at the screening visit&#xD;
&#xD;
          -  Negative urine tests for selected drugs of abuse and alcohol breath test at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant medical or psychiatric condition that could, in the Investigator's&#xD;
             opinion, compromise the subject's safety or interfere with the completion of this&#xD;
             protocol.&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities or pulmonary&#xD;
             condition, which according to the Investigator places the subject at unacceptable risk&#xD;
             if he/she were to participate in the study.&#xD;
&#xD;
          -  A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of&#xD;
             the Investigator could compromise the subject's safety or interfere with the&#xD;
             interpretation of safety or efficacy data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Carter, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Nelson</last_name>
    <phone>650-730-5508</phone>
    <email>mnelson@alexza.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Om Research</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93535</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Toc</last_name>
      <phone>661-388-2239</phone>
      <phone_ext>08</phone_ext>
      <email>info@omclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Jatinder S. Pruthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elianet De La Cruz</last_name>
      <phone>310-289-8242</phone>
      <email>eli@axistoday.com</email>
    </contact>
    <investigator>
      <last_name>Lydie Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josie Summers</last_name>
      <phone>619-501-0371</phone>
      <phone_ext>309</phone_ext>
      <email>josie@prisandiego.com</email>
    </contact>
    <investigator>
      <last_name>Taddese Desta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thanh Tran</last_name>
      <phone>813-844-8544</phone>
      <email>tqtran@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Vic Velanovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Studies</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Wilson, MSc CROM</last_name>
      <phone>706-400-4262</phone>
      <email>info@summitclinicalstudies.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinite Clinical Trials</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Russell, NCMA, CRC</last_name>
      <phone>678-430-3232</phone>
      <email>srussell@infiniteclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Marie Walton, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Torneden</last_name>
      <phone>913-574-0533</phone>
      <email>jtorneden2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Reza Hejazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Kiser</last_name>
      <phone>617-724-0480</phone>
      <email>KKISER@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Braden Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Wilson</last_name>
      <phone>313-404-9110</phone>
      <email>kwilso10@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Breen-Lyles</last_name>
      <phone>507-293-0237</phone>
      <email>breen-lyles.margaret@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Madhusudan Grover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NY Scientific</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Hossain</last_name>
      <phone>347-547-6972</phone>
      <email>mhossain@nyscientific.net</email>
    </contact>
    <investigator>
      <last_name>Alex Brun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley Fesi</last_name>
      <phone>215-707-2411</phone>
      <email>bradley.fesi@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Parkman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Snyder</last_name>
      <email>lbs18@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>David Levinthal, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Phase Research &amp; Development, LLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Wilkerson</last_name>
      <phone>865-200-8364</phone>
      <email>lwilkerson@newphaseonline.com</email>
    </contact>
    <investigator>
      <last_name>Evelyne M. Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mercado</last_name>
      <phone>713-798-3606</phone>
      <email>michael.mercado@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Mohamed Othman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khurram Shah</last_name>
      <phone>713-333-9323</phone>
      <email>khurram@pioneerresearchsolutions.com</email>
    </contact>
    <investigator>
      <last_name>Subodh Bhuchar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sante Clinical Research</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Monclova</last_name>
      <phone>830-890-5171</phone>
      <email>dmonclova@santeresearch.net</email>
    </contact>
    <investigator>
      <last_name>Carlos Menendez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Bruss</last_name>
      <phone>414-805-7128</phone>
      <email>abruss@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Thangam Venkatesan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cvshope.com</url>
    <description>CVS study web-site</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclic Vomiting Syndrome</keyword>
  <keyword>CVS</keyword>
  <keyword>Vomiting</keyword>
  <keyword>Retching</keyword>
  <keyword>Abdominal migraine</keyword>
  <keyword>Nausea</keyword>
  <keyword>Stomach pain</keyword>
  <keyword>Unexplained vomiting</keyword>
  <keyword>Functional GI Disorder</keyword>
  <keyword>CVSHOPE.com</keyword>
  <keyword>Throwing up</keyword>
  <keyword>Puking</keyword>
  <keyword>Dry heaving</keyword>
  <keyword>Food poisoning</keyword>
  <keyword>Episodes</keyword>
  <keyword>Repeated food poisoning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

